| Year |
Citation |
Score |
| 2023 |
Dao T, Xiong G, Mun SS, Meyerberg J, Korontsvit T, Xiang J, Cui Z, Chang AY, Jarvis CA, Cai W, Luo H, Pierson AJ, Daniyan AF, Yoo S, Takao S, et al. Dual-receptor T cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML. Blood. PMID 38048594 DOI: 10.1182/blood.2023021054 |
0.683 |
|
| 2021 |
Gardner TJ, Lee JP, Bourne CM, Wijewarnasuriya D, Kinarivala N, Kurtz KG, Corless BC, Dacek MM, Chang AY, Mo G, Nguyen KM, Brentjens RJ, Tan DS, Scheinberg DA. Engineering CAR-T cells to activate small-molecule drugs in situ. Nature Chemical Biology. PMID 34969970 DOI: 10.1038/s41589-021-00932-1 |
0.65 |
|
| 2021 |
Chang AY, Zhou YJ, Iyengar S, Pobiarzyn PW, Tishchenko P, Shah KM, Wheeler H, Wang YM, Loria PM, Loganzo F, Woo SR. Modulation of SF3B1 in the pre-mRNA spliceosome induces a RIG-I-dependent type I IFN response. The Journal of Biological Chemistry. 101277. PMID 34619148 DOI: 10.1016/j.jbc.2021.101277 |
0.558 |
|
| 2020 |
Gejman RS, Jones HF, Klatt MG, Chang AY, Oh CY, Chandran SS, Korontsvit T, Zakahleva V, Dao T, Klebanoff CA, Scheinberg DA. Identification of the targets of T cell receptor therapeutic agents and cells by use of a high throughput genetic platform. Cancer Immunology Research. PMID 32184297 DOI: 10.1158/2326-6066.Cir-19-0745 |
0.783 |
|
| 2020 |
Mondello P, Tadros S, Teater M, Fontan L, Chang AY, Jain N, Yang H, Singh S, Ying HY, Chu CS, Ma MCJ, Toska E, Alig S, Durant M, de Stanchina E, et al. Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma. Cancer Discovery. PMID 31915197 DOI: 10.1158/2159-8290.Cd-19-0116 |
0.571 |
|
| 2019 |
Oh CY, Klatt MG, Bourne C, Dao T, Dacek MM, Brea EJ, Mun SS, Chang AY, Korontsvit T, Scheinberg DA. ALK and RET inhibitors promote HLA class I antigen presentation and unmask new antigens within the tumor immunopeptidome. Cancer Immunology Research. PMID 31540894 DOI: 10.1158/2326-6066.Cir-19-0056 |
0.67 |
|
| 2018 |
Gejman RS, Chang AY, Jones HF, DiKun K, Hakimi AA, Schietinger A, Scheinberg DA. Rejection of immunogenic tumor clones is limited by clonal fraction. Elife. 7. PMID 30499773 DOI: 10.7554/Elife.41090 |
0.782 |
|
| 2018 |
Mondello P, Brea EJ, De Stanchina E, Toska E, Chang AY, Fennell M, Seshan V, Garippa R, Scheinberg DA, Baselga J, Wendel HG, Younes A. Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations. Jci Insight. 3. PMID 30429379 DOI: 10.1172/jci.insight.125568 |
0.454 |
|
| 2018 |
Macal M, Jo Y, Dallari S, Chang AY, Dai J, Swaminathan S, Wehrens EJ, Fitzgerald-Bocarsly P, Zúñiga EI. Self-Renewal and Toll-like Receptor Signaling Sustain Exhausted Plasmacytoid Dendritic Cells during Chronic Viral Infection. Immunity. 48: 730-744.e5. PMID 29669251 DOI: 10.1016/J.Immuni.2018.03.020 |
0.646 |
|
| 2018 |
Gejman RS, Chang AY, Jones HF, DiKun K, Hakimi AA, Schietinger A, Scheinberg DA. Author response: Rejection of immunogenic tumor clones is limited by clonal fraction Elife. DOI: 10.7554/Elife.41090.026 |
0.722 |
|
| 2017 |
Chang AY, Dao T, Gejman RS, Jarvis CA, Scott A, Dubrovsky L, Mathias MD, Korontsvit T, Zakhaleva V, Curcio M, Hendrickson RC, Liu C, Scheinberg DA. A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens. The Journal of Clinical Investigation. 127: 3557. PMID 28862643 DOI: 10.1172/JCI96860 |
0.794 |
|
| 2017 |
Mathias MD, Sockolosky JT, Chang AY, Tan KS, Liu C, Garcia KC, Scheinberg DA. CD47 blockade enhances therapeutic activity of TCR mimic antibodies to ultra low density cancer epitopes. Leukemia. PMID 28745331 DOI: 10.1016/J.Clml.2016.07.013 |
0.577 |
|
| 2017 |
Chang AY, Dao T, Gejman RS, Jarvis CA, Scott A, Dubrovsky L, Mathias MD, Korontsvit T, Zakhaleva V, Curcio M, Hendrickson RC, Liu C, Scheinberg DA. A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens. The Journal of Clinical Investigation. PMID 28628042 DOI: 10.1172/Jci92335 |
0.8 |
|
| 2017 |
Mondello P, Brea EJ, De Stanchina E, Toska E, Chang AY, Fennell M, Seshan V, Garippa R, Scheinberg DA, Baselga J, Wendel HG, Younes A. Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265 mutations. Jci Insight. 2: e90196. PMID 28352655 DOI: 10.1172/Jci.Insight.90196 |
0.534 |
|
| 2016 |
Brea EJ, Oh CY, Manchado E, Budhu S, Gejman RS, Mo G, Mondello P, Han JE, Jarvis CA, Ulmert D, Xiang Q, Chang AY, Garippa RJ, Merghoub T, Wolchok JD, et al. Kinase regulation of Human MHC Class I Molecule Expression on Cancer Cells. Cancer Immunology Research. PMID 27680026 DOI: 10.1158/2326-6066.Cir-16-0177 |
0.777 |
|
| 2016 |
Dubrovsky L, Dao T, Gejman RS, Brea EJ, Chang AY, Oh CY, Casey E, Pankov D, Scheinberg DA. T cell receptor mimic antibodies for cancer therapy. Oncoimmunology. 5: e1049803. PMID 26942058 DOI: 10.1080/2162402X.2015.1049803 |
0.797 |
|
| 2016 |
Mathias MD, Sockolosky JT, Chang AY, Liu C, Garcia KC, Scheinberg DA. CD47 Blockade Enhances Therapeutic Activity of TCR Mimic Antibodies to Ultra-Low Density Cancer Epitopes through Cytokine Feed Forward Mechanisms Blood. 128: 4048-4048. DOI: 10.1182/Blood.V128.22.4048.4048 |
0.681 |
|
| 2016 |
Dubrovsky L, Dao T, Gejman RS, Brea EJ, Chang AY, Oh CY, Casey E, Pankov D, Scheinberg DA. T cell receptor mimic antibodies for cancer therapy Oncoimmunology. 5. DOI: 10.1080/2162402X.2015.1049803 |
0.768 |
|
| 2016 |
Mathias M, Sockolosky J, Chang A, Liu C, Garcia K, Scheinberg D. CD47 Blockade Enhances Therapeutic Activity of TCR Mimic Antibodies to Ultra-Low Density Cancer Epitopes Clinical Lymphoma Myeloma and Leukemia. 16: S8. DOI: 10.1016/j.clml.2016.07.013 |
0.532 |
|
| 2015 |
Chang A, Dao T, Scott A, Dubrovsky L, Liu C, Scheinberg DA. A Therapeutic TCR Mimic Monoclonal Antibody for Intracellular PRAME Protein in Leukemias Blood. 126: 2527-2527. DOI: 10.1182/Blood.V126.23.2527.2527 |
0.635 |
|
| Show low-probability matches. |